PMID- 38167571
OWN - NLM
STAT- MEDLINE
DCOM- 20240105
LR  - 20240116
IS  - 2523-3106 (Electronic)
IS  - 2523-3106 (Linking)
VI  - 64
IP  - 1
DP  - 2024 Jan 2
TI  - Patients with longstanding pPatients with longstanding psoriatic arthritis can 
      achieve DAPSA remission or low disease activity and it correlates to better 
      functional outcomes: results from a Latin-American real-life cohort.
PG  - 3
LID - 10.1186/s42358-023-00338-8 [doi]
AB  - BACKGROUND: Patients with psoriatic arthritis (PsA) experience reduced physical 
      function and impaired quality of life. Better patient-reported functional 
      outcomes are found when lower disease activity is achieved. OBJECTIVES: To 
      evaluate the variation of physical function by HAQ-DI over time in PsA patients 
      treated with standard therapy in a real-life setting: to verify predictors of 
      achieving a minimum clinically important difference (MCID) in function by HAQ-DI 
      (DeltaHAQ-DI </= - 0.35) and to measure the impact of achieving REM/LDA on long-term 
      function by HAQ-DI. METHODS: This is a longitudinal analysis of a real-life 
      retrospective cohort. Data from PsA patients with at least 4 years of follow-up 
      in the PsA clinic from 2011 to 2019 were extracted from electronic medical 
      records. The variations of physical function by HAQ-DI and disease activity by 
      DAPSA over time were calculated. A multivariate hierarchical regression model was 
      applied to verify predictors of MCID in HAQ-DI. A comparison of HAQ-DI variation 
      between patients with DAPSA REM, LDA, moderate and high disease activity was made 
      using the generalized estimating equation model (GEE), adjusted by Bonferroni 
      test. The Spearman correlation method was applied to verify the correlation of 
      DeltaDAPSA and DeltaHAQ-DI over time. Statistical analysis was performed in SPSS program 
      version 21.0. RESULTS: Seventy-three patients were included in the analysis. 
      Physical function measured by HAQ-DI was determined by PsA disease activity 
      measured by DAPSA (p < 0.000). A moderate and statistically significant 
      correlation between DeltaDAPSA and DeltaHAQ-DI was observed (r(s) = 0.60; p < 0.001). 
      Only patients in DAPSA REM demonstrated a constant decline in HAQ-DI scores 
      during the follow-up. White ethnicity and older age at baseline were predictors 
      for not achieving MCID in HAQ-DI [RR 0.33 (0.16-0.6795% CI p = 0.002) and RR 0.96 
      (0.93-0.9895% CI p < 0.000), respectively, while higher scores of HAQ-DI at 
      baseline were predictors of achieving MCID [RR 1.71 (1.12-2.6095%CI p = 0.013)]. 
      CONCLUSIONS: In PsA, patients who maintained DAPSA REM/LDA over time had better 
      long-term functional outcomes. Higher HAQ-DI scores at baseline, non-white 
      ethnicity and younger age were predictors for achieving a clinical meaningful 
      improvement of HAQ-DI.
CI  - (c) 2023. The Author(s).
FAU - Cruz, Larissa Vargas
AU  - Cruz LV
AUID- ORCID: 0000-0003-2472-9368
AD  - Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil. 
      larissavargascruz@gmail.com.
FAU - Farani, Julia Boechat
AU  - Farani JB
AD  - Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
FAU - Costa, Julia Rabello
AU  - Costa JR
AD  - Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, 
      Brazil.
FAU - de Andrade Aguas, Joao Victor
AU  - de Andrade Aguas JV
AD  - Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, 
      Brazil.
FAU - Ruschel, Bruna
AU  - Ruschel B
AD  - Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, 
      Brazil.
FAU - de Almeida Menegat, Franciele
AU  - de Almeida Menegat F
AD  - Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
FAU - Gasparin, Andrese Aline
AU  - Gasparin AA
AD  - Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
FAU - Brenol, Claiton Viegas
AU  - Brenol CV
AD  - Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
AD  - Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, 
      Brazil.
FAU - Kohem, Charles Lubianca
AU  - Kohem CL
AD  - Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
AD  - Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, 
      Brazil.
FAU - Bessa, Adrieli
AU  - Bessa A
AD  - Novartis Biociencias, Porto Alegre, Brazil.
FAU - Forestiero, Francisco
AU  - Forestiero F
AD  - Novartis Biociencias, Porto Alegre, Brazil.
FAU - Thies, Felipe
AU  - Thies F
AD  - Novartis Biociencias, Porto Alegre, Brazil.
FAU - Palominos, Penelope Esther
AU  - Palominos PE
AD  - Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20240102
PL  - England
TA  - Adv Rheumatol
JT  - Advances in rheumatology (London, England)
JID - 101734172
RN  - 0 (Antirheumatic Agents)
SB  - IM
MH  - Humans
MH  - United States
MH  - *Arthritis, Psoriatic/drug therapy
MH  - *Antirheumatic Agents/therapeutic use
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Arthritis
OT  - Disability evaluation
OT  - Disease activity
OT  - Function
OT  - Patient reported outcome measures
OT  - Psoriatic
EDAT- 2024/01/04 01:18
MHDA- 2024/01/05 06:42
CRDT- 2024/01/03 09:58
PHST- 2023/03/04 00:00 [received]
PHST- 2023/11/13 00:00 [accepted]
PHST- 2024/01/05 06:42 [medline]
PHST- 2024/01/04 01:18 [pubmed]
PHST- 2024/01/03 09:58 [entrez]
AID - 10.1186/s42358-023-00338-8 [pii]
AID - 10.1186/s42358-023-00338-8 [doi]
PST - epublish
SO  - Adv Rheumatol. 2024 Jan 2;64(1):3. doi: 10.1186/s42358-023-00338-8.